These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 17301549)

  • 1. [Innovation of clinical trials for anti-cancer drugs in Japan--proposals from academia with special reference to the development of novel Bcr-Abl/Lyn tyrosine kinase inhibitor INNO-406 (NS-187) for imatinib-resistant chronic myelogenous leukemia].
    Maekawa T
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):301-4. PubMed ID: 17301549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.
    Maekawa T; Ashihara E; Kimura S
    Int J Clin Oncol; 2007 Oct; 12(5):327-40. PubMed ID: 17929114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
    Yokota A; Kimura S; Masuda S; Ashihara E; Kuroda J; Sato K; Kamitsuji Y; Kawata E; Deguchi Y; Urasaki Y; Terui Y; Ruthardt M; Ueda T; Hatake K; Inui K; Maekawa T
    Blood; 2007 Jan; 109(1):306-14. PubMed ID: 16954504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
    Jabbour E; Cortes J; O'Brien S; Giles F; Kantarjian H
    Semin Hematol; 2007 Jan; 44(1 Suppl 1):S25-31. PubMed ID: 17292738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
    Deguchi Y; Kimura S; Ashihara E; Niwa T; Hodohara K; Fujiyama Y; Maekawa T
    Leuk Res; 2008 Jun; 32(6):980-3. PubMed ID: 18191450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted drugs in chronic myeloid leukemia.
    Gora-Tybor J; Robak T
    Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
    Kimura S; Ashihara E; Maekawa T
    Curr Pharm Biotechnol; 2006 Oct; 7(5):371-9. PubMed ID: 17076652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
    Morinaga K; Yamauchi T; Kimura S; Maekawa T; Ueda T
    Int J Cancer; 2008 Jun; 122(11):2621-7. PubMed ID: 18338755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
    Rix U; Hantschel O; Dürnberger G; Remsing Rix LL; Planyavsky M; Fernbach NV; Kaupe I; Bennett KL; Valent P; Colinge J; Köcher T; Superti-Furga G
    Blood; 2007 Dec; 110(12):4055-63. PubMed ID: 17720881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
    Soverini S; Rosti G; Iacobucci I; Baccarani M; Martinelli G
    Oncologist; 2011; 16(6):868-76. PubMed ID: 21632458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
    O'Hare T; Walters DK; Stoffregen EP; Jia T; Manley PW; Mestan J; Cowan-Jacob SW; Lee FY; Heinrich MC; Deininger MW; Druker BJ
    Cancer Res; 2005 Jun; 65(11):4500-5. PubMed ID: 15930265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming kinase resistance in chronic myeloid leukemia.
    Lee F; Fandi A; Voi M
    Int J Biochem Cell Biol; 2008; 40(3):334-43. PubMed ID: 18401881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.
    Levinson NM; Boxer SG
    PLoS One; 2012; 7(4):e29828. PubMed ID: 22493660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy options in imatinib failures.
    Ramirez P; DiPersio JF
    Oncologist; 2008 Apr; 13(4):424-34. PubMed ID: 18448557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
    Wu J; Meng F; Kong LY; Peng Z; Ying Y; Bornmann WG; Darnay BG; Lamothe B; Sun H; Talpaz M; Donato NJ
    J Natl Cancer Inst; 2008 Jul; 100(13):926-39. PubMed ID: 18577747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.
    Mahon FX; Hayette S; Lagarde V; Belloc F; Turcq B; Nicolini F; Belanger C; Manley PW; Leroy C; Etienne G; Roche S; Pasquet JM
    Cancer Res; 2008 Dec; 68(23):9809-16. PubMed ID: 19047160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
    DeAngelo DJ; Attar EC
    Leuk Lymphoma; 2010 Mar; 51(3):363-75. PubMed ID: 20038231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
    Kujawski L; Talpaz M
    Leuk Lymphoma; 2007 Dec; 48(12):2310-22. PubMed ID: 18067005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.